Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

How useful is ε-aminocaproic acid for the treatment of hyperfibrinolysis in patients with cirrhosis?

Nature Clinical Practice Gastroenterology & Hepatology volume 3, pages 370–371 (2006)Cite this article

boxed-textGunawan B and Runyon B (2006) The efficacy and safety of ε-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis. Aliment Pharmacol Ther 23: 115–120

Testing for hyperfibrinolysis should be performed in patients with cirrhosis and persistent mucosal or cutaneous bleeding; treatment with ε-aminocaproic acid is well tolerated and might be efficacious in this setting

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tripodi A et al. (2005) Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 41: 553–558

    Article  CAS  Google Scholar 

  2. Hu KQ et al. (2001) Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 96: 1581–1586

    Article  CAS  Google Scholar 

  3. Violi F et al. (1993) Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis. Hepatology 17: 78–83

    Article  CAS  Google Scholar 

  4. Youssef WI et al. (2003) Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol 98: 1391–1394

    Article  Google Scholar 

  5. Caldwell SH et al. (2004) Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials. Hepatology 39: 592–598

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Assistant Professor,

    Patrick G Northup & Stephen H Caldwell

  2. Director of Hepatology and an Associate Professor in the Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, VA, USA

    Patrick G Northup & Stephen H Caldwell

Authors
  1. Patrick G Northup
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen H Caldwell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick G Northup.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Northup, P., Caldwell, S. How useful is ε-aminocaproic acid for the treatment of hyperfibrinolysis in patients with cirrhosis?. Nat Rev Gastroenterol Hepatol 3, 370–371 (2006). https://doi.org/10.1038/ncpgasthep0526

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0526

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing